They later carried out a preclinical study about intraperitoneal (IP) delivery of CEA CAR-T cells against peritoneal carcinomatosis on the basis above, showed superior anti-tumor efficacy against CEA+ peritoneal tumors, prolonged protection against tumor re-challenges, and effector memory T (Tcm) cells increased over time when compared with systemic infusion 112. This evidence concerns the gene CEACAM5 and neoplasm.